"We are thrilled to partner with Icon," said Joe Ianni, VP Global Sales & Strategic Partnerships for Radformation. "Their global reputation for excellence and commitment to innovation aligns seamlessly with our vision for advancing radiation oncology workflows. Together, we have the opportunity to improve the way cancer treatment is delivered and further empower clinicians in their mission to save lives."
About Radformation
![](https://cdn.dotmed.com/images/spacer.jpg)
Ad Statistics
Times Displayed: 41009
Times Visited: 663 Reveal Mobi Pro integrates the Reveal 35C detector with SpectralDR technology into a modern mobile X-ray solution. Mobi Pro allows for simultaneous acquisition of conventional & dual-energy images with a single exposure. Contact us for a demo at no cost.
Radformation is committed to improving the lives of clinicians by delivering user-friendly products developed to increase the safety and quality of cancer treatment. Radformation envisions a radiation oncology clinic where staff are equipped with solutions that supplement their expertise and automate tedious tasks, leading to better patient care everywhere. Since its founding in 2016, Radformation has grown to serve over 1,600 clinics around the world with a portfolio of products streamlining all stages of the treatment planning workflow.
About Icon Group
Icon Group is Australia's largest integrated provider of cancer care with a growing reach in New Zealand, Asia and the United Kingdom. Icon is built on a strong but simple mission - to deliver the best care possible to as many people as possible, as close to home as possible. The group brings together all aspects of quality cancer care including medical oncology, haematology, radiation oncology, research, pharmacy and compounding to deliver a truly integrated, end-to-end seamless service for cancer patients. With a network of more than 300 doctors, over 50 cancer centres, four compounding facilities and the management of 70 plus pharmacies, Icon is delivering world-leading care and helping address the global cancer burden.
Back to HCB News